Clemmensen I - Search Results

1

[Tetranectin, a plasma and tissue protein--a prognostic marker of breast and ovarian cancer].

Høgdall CK, Christensen L, Clemmensen I. Høgdall CK, et al. Among authors: clemmensen i. Ugeskr Laeger. 1994 Oct 17;156(42):6190-5. Ugeskr Laeger. 1994. PMID: 7998355 Review. Danish.

2

Differences in tetranectin immunoreactivity between benign and malignant breast tissue.

Christensen L, Clemmensen I. Christensen L, et al. Among authors: clemmensen i. Histochemistry. 1991;95(5):427-33. doi: 10.1007/BF00315737. Histochemistry. 1991. PMID: 1651300

3

Tetranectin immunoreactivity in normal human tissues. An immunohistochemical study of exocrine epithelia and mesenchyme.

Christensen L, Clemmensen I. Christensen L, et al. Among authors: clemmensen i. Histochemistry. 1989;92(1):29-35. doi: 10.1007/BF00495012. Histochemistry. 1989. PMID: 2670845

4

Changes in plasma tetranectin following hip surgery with or without thrombotic complications.

Høgdall CK, Høgdall EV, Jørgensen LN, Clemmensen I. Høgdall CK, et al. Among authors: clemmensen i. Thromb Res. 1992 Aug 15;67(4):399-405. doi: 10.1016/0049-3848(92)90269-g. Thromb Res. 1992. PMID: 1412218

5

Plasma tetranectin and ovarian neoplasms.

Høgdall CK, Høgdall EV, Hørding U, Daugaard S, Clemmensen I, Nørgaard-Pedersen B, Toftager-Larsen K. Høgdall CK, et al. Among authors: clemmensen i. Gynecol Oncol. 1991 Nov;43(2):103-7. doi: 10.1016/0090-8258(91)90053-8. Gynecol Oncol. 1991. PMID: 1743549

6

Tetranectin in amniotic fluid, maternal serum and fetal fluids.

Høgdall EV, Høgdall CK, Clemmensen I, Nørgaard-Pedersen B, Loft AG. Høgdall EV, et al. Among authors: clemmensen i. Scand J Clin Lab Invest. 1991 Sep;51(5):411-5. doi: 10.3109/00365519109091634. Scand J Clin Lab Invest. 1991. PMID: 1947725

7

Plasma tetranectin and colorectal cancer.

Høgdall CK, Christiansen M, Nørgaard-Pedersen B, Bentzen SM, Kronborg O, Clemmensen I. Høgdall CK, et al. Among authors: clemmensen i. Eur J Cancer. 1995 Jun;31A(6):888-94. doi: 10.1016/0959-8049(94)00520-6. Eur J Cancer. 1995. PMID: 7646916

8

Serum tetranectin and CA-125 used to monitor the course of treatment in ovarian cancer patients.

Høgdall CK, Hørding U, Nørgaard-Pedersen B, Toftager-Larsen K, Clemmensen I. Høgdall CK, et al. Among authors: clemmensen i. Eur J Obstet Gynecol Reprod Biol. 1994 Dec;57(3):175-8. doi: 10.1016/0028-2243(94)90296-8. Eur J Obstet Gynecol Reprod Biol. 1994. PMID: 7713292

9

The role of serum tetranectin, CA 125, and a combined index as tumor markers in women with pelvic tumors.

Høgdall CK, Mogensen O, Tabor A, Mogensen B, Jakobsen AK, Nørgaard-Pedersen B, Larsen SO, Clemmensen I. Høgdall CK, et al. Among authors: clemmensen i. Gynecol Oncol. 1995 Jan;56(1):22-8. doi: 10.1006/gyno.1995.1004. Gynecol Oncol. 1995. PMID: 7821842

10

Prognostic value of serum tetranectin in patients with metastatic breast cancer.

Høgdall CK, Sölétormos G, Nielsen D, Nørgaard-Pedersen B, Dombernowsky P, Clemmensen I. Høgdall CK, et al. Among authors: clemmensen i. Acta Oncol. 1993;32(6):631-6. doi: 10.3109/02841869309092443. Acta Oncol. 1993. PMID: 8260181 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123 results

Search Page

Filters